Rallybio Corp (RLYB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Rallybio Corp stock (RLYB) is currently trading at $8.63. Rallybio Corp PS ratio (Price-to-Sales) is 56.16. Analyst consensus price target for RLYB is $8.00. WallStSmart rates RLYB as Sell.
- RLYB PE ratio analysis and historical PE chart
- RLYB PS ratio (Price-to-Sales) history and trend
- RLYB intrinsic value — DCF, Graham Number, EPV models
- RLYB stock price prediction 2025 2026 2027 2028 2029 2030
- RLYB fair value vs current price
- RLYB insider transactions and insider buying
- Is RLYB undervalued or overvalued?
- Rallybio Corp financial analysis — revenue, earnings, cash flow
- RLYB Piotroski F-Score and Altman Z-Score
- RLYB analyst price target and Smart Rating
Rallybio Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Rallybio Corp (RLYB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Rallybio Corp (RLYB) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 484.20% year-over-year
63.65% held by institutions, strong professional interest
Supporting Valuation Data
Rallybio Corp (RLYB) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 56.2x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Rallybio Corp (RLYB) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 9.3/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth, Institutional Own.. Valuation metrics including Price/Book (0.81) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 484.20%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (56.16) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -15.00%, Operating Margin at -2888.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -15.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 484.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RLYB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RLYB's Price-to-Sales ratio of 56.16x trades 20% below its historical average of 69.85x (14th percentile). The current valuation is 34% below its historical high of 85.47x set in Mar 2026, and 0% above its historical low of 56.04x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Rallybio Corp (RLYB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Rallybio Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 858,000 with 484% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 484% YoY, reaching 858,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.00 indicates a conservative balance sheet with 31M in cash.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Rallybio Corp maintain 484%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Rallybio Corp.
Bottom Line
Rallybio Corp is a high-conviction growth story with revenue accelerating at 484% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Rallybio Corp(RLYB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, specifically targeting unmet medical needs in immunology and hematology. The company boasts a robust pipeline of biologic drug candidates advancing through clinical stages, supported by a seasoned management team with strong industry expertise. Strategic collaborations strengthen Rallybio's capabilities in delivering transformative treatments, ultimately aiming to enhance patient outcomes. With a clear commitment to underserved therapeutic areas, Rallybio is well-positioned to make significant contributions to the healthcare sector while paving the way toward commercial success.